+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report

  • ID: 2895274
  • Report
  • 219 Pages
  • VeracityHealth
1 of 4

FEATURED COMPANIES

  • Affymetrix Inc
  • Cancer Genetics, Inc
  • Epigenomics
  • Ipsogen (Qiagen)
  • Novartis Diagnostics
  • Siemens
  • MORE
The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used for the detection and diagnosis of cancer, and the impact on making the ongoing research closer to clinical application.

The report will also provide a market analysis of the market value, growth rates, market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry players, and the factors influencing the market shares of both the major market suppliers and smaller indigenous manufacturers in local markets.

The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models.

The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Affymetrix Inc
  • Cancer Genetics, Inc
  • Epigenomics
  • Ipsogen (Qiagen)
  • Novartis Diagnostics
  • Siemens
  • MORE
Executive Summary
ES.1 Introduction to the Circulating Nucleic Acid Market Report
ES.2 Background to Circulating Nucleic Acids
ES.3 Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
ES.4 CNA Based Cancer Diagnostics Market: Revenue Analysis
Exhibit E.S. 1: Global Market Revenue Forecast - CNA Based Non-invasive Cancer Diagnostic
Products (2010 – 2020)
ES.5 CNA Based Cancer Diagnostics Market: Market Share Analysis
Exhibit E.S. 2: Global Market Share Analysis – CNA Based Non-invasive Cancer Diagnostic Products (2013)
Exhibit E.S. 3: Global Market Share Analysis – CNA Based Non-invasive Cancer Diagnostic Products (2013)
ES.6 Company Profiles

Chapter 1: Introduction to the Circulating Nucleic Acid Market Report
1.1 Report Background
1.2 Report Objectives and Deliverables
1.3 Methodology

Chapter 2: Background to Circulating Nucleic Acids
2.1 Introduction to Circulating Nucleic Acids (CNAs)
Exhibit 2.1: Major Developments in Understanding Nucleic Acids and their Cellular Roles
Exhibit 2.2: Circulating DNA Concentrations in Blood of Healthy Donors and Selected Cancer Patients
2.2 Categories of Circulating Nucleic Acids
2.2.1 Circulating Cell-Free DNA
2.2.2 Circulating Extracellular DNA
2.2.3 RNA
2.2.3.1 microRNAs (miRNAs)
2.2.3.2 miRNA Mimics and Inhibitors
2.2.3.3 Small Interfering RNA (siRNA)
2.2.3.4 RNA Interference (RNAi)
2.3 Circulating Nucleic Acids as a Diagnostic Tool
2.3.1 Circulating DNA as a Biomarker of Cancer
2.3.2 Use of Circulating DNA for Prenatal Diagnosis
2.3.3 Circulating RNA as a Biomarker of Cancer
Exhibit 2.3: Circulating Tumour-Associated miRNAs as potential biomarkers in Lung Cancer
Exhibit 2.4: Circulating Tumour-Associated miRNAs as potential biomarkers in Breast Cancer
Exhibit 2.5: Circulating Tumour-Associated miRNAs as potential biomarkers in Prostate Cancer
Exhibit 2.6: Circulating Tumour-Associated miRNAs as potential biomarkers in Ovarian Cancer
Exhibit 2.7: Circulating Tumour-Associated miRNAs as potential biomarkers in Bladder Cancer
Exhibit 2.8: Circulating Tumour-Associated miRNAs as potential biomarkers in Pancreatic Cancer
Exhibit 2.9: Circulating Tumour-Associated miRNAs as potential biomarkers in Gastric Cancer
Exhibit 2.10: Circulating Tumour-Associated miRNAs as potential biomarkers in Liver Cancer
Exhibit 2.11: Circulating Tumour-Associated miRNAs as potential biomarkers in Colo-Rectal Cancer
Exhibit 2.12: Circulating Tumour-Associated miRNAs as potential biomarkers in Oral Cancer
Exhibit 2.13: Circulating Tumour-Associated miRNAs as potential biomarkers in Esophageal Cancer
Exhibit 2.3.4 Circulating RNA in Pregnancy
Exhibit 2.4 Methods Used for the Detection of Circulating Nucleic Acids
Exhibit 2.4: Top molecular CNA Characterisation Techniques
Exhibit 2.5: Top molecular CNA Characterisation Techniques

Chapter 3: Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
3.1 Introduction
3.2 Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence
Exhibit 3.1: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (2012)
3.2.1 Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Both Sexes) by Cancer Type
Exhibit 3.2: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
3.2.2 Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Male) by Cancer
Exhibit 3.3: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (By Male) by Cancer Type (2012)
3.2.3 Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.4: Summary Statistics: Estimated Incidence, Mortality and 5-year Prevalence (By Female) by Cancer Type (2012)
3.3 WHO Americas Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.5: WHO Americas Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
3.4 WHO European Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.6: WHO European Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
3.5 WHO African Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.7: WHO African Region Summary Statistics (Global): Estimated Incidence, Mortality and 5 year Prevalence (Both Sexes)by Cancer Type (2012)
3.6 WHO Eastern Mediterranean Region Summary Statistics: Estimated Incidence, Mortality and 5 Year Prevalence by Cancer Type
3.7 WHO South East Asia Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.8: WHO Eastern Mediterranean Eastern Mediterranean Region Summary Statistics
(Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
Exhibit 3.9: WHO South East Asia Region Summary Statistics (Global): Estimated Incidence,
Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
3.8 WHO Western Pacific Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
Exhibit 3.10: WHO Western Pacific Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)

Chapter 4: CNA Based Cancer Diagnostics Market: Revenue Analysis
4.1 Introduction
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.1.1 Evolving Paradigm Shift in Disease Diagnostics
4.2.1.2 Significant Advantages over Conventional Screening and Diagnostic Methods
4.2.1.3 Research and Development of New and Innovative Enabling Technologies
4.2.2 Market Restraints
4.2.2.1 Securing Appropriate Reimbursement Schedules
4.2.2.2 Social, Ethical and Regulatory Issue for Implementation of Circulating Nucleic Acid Diagnostic Technologies
4.2.2.3 Technical Issues: Sample Collection, Handling, Extraction, Transportation and Storage etc
Cause Concerns over Practical Use of Circulating Nucleic Acids
4.3 Selected CNA Cancer Diagnostic Products
Exhibit 4.1: Featured CNA Cancer Diagnostic Products
4.4 Market Revenue Analysis
4.4.1 Global Market Revenue Analysis
4.4.1.1 Total Market Revenue Analysis
Exhibit 4.2: Global Market Revenue Forecast (2010 – 2020)
4.1.1 Market Revenue Analysis by Geographic Region
Exhibit 4.3: Global Market Revenue Forecast (2009 – 2019)
Exhibit 4.4: Market Revenue Forecast by Geographic Countries - (2010 – 2020)
Exhibit 4.5: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA
Based Cancer Diagnostics (2010 – 2020)
Exhibit 4.6: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA
Based Cancer Diagnostics (2010 – 2020)
4.1.2 Market Revenue Analysis by Selected Country
Exhibit 4.6: Market Revenue Forecast by Selected Countries - (2010 – 2020)
Exhibit 4.7: Market Revenue Forecast by Selected Countries - (2010 – 2020)

Chapter 5: CNA Based Cancer Diagnostics Market: Market Share Analysis
5.1 Market Share Analysis
5.1.1 Global Market Share Analysis
Exhibit 5.1: Global Market Share Analysis – CNA Based Non-invasive Cancer Diagnostic Products (2013)
Exhibit 5.2: Global Market Share Analysis – CNA Based Non-invasive Cancer Diagnostic Products (2013)
5.5.2 Market Share Analysis by Geographic Region
Exhibit 5.3: Market Share Analysis by Geographic Region - Non-invasive Cancer Diagnostic Diagnostics (2013)
5.5.3 Market Share Analysis by Selected Country
Exhibit 5.4: Market Share Analysis by Selected Country - Non-invasive Prenatal Diagnostics (2013)

Chapter 6: Company Profiles
6.1 Abbott Laboratories (Abbott Molecular)
6.2 Affymetrix Inc
6.3 Autogenomics
6.4 Becton Dickinson and Company (BD)
6.5 Beckmann Coulter, Inc (Danaher Corporation)
6.6 bioMérieux
6.7 Cancer Genetics, Inc
6.8 Cepheid
6.9 Dako (Agilent)
6.10 Epigenomics
6.11 Hologic Gen-Probe
6.12 Illumina
6.13 Ipsogen (Qiagen)
6.14 Luminex
6.15 MolecularMD
6.16 Myriad Genetics Laboratories
6.17 Novartis Diagnostics
6.18 Ortho-Clinical Diagnostics (The Carlyle Group)
6.19 Oxford Gene Technology (OGT)
6.20 Qiagen N.V.
6.21 Roche
6.22 Siemens
6.23 Sysmex Corporation
6.24 Thermo Fisher Scientific
6.25 Ventana (Roche)

Glossary of Acronyms
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Abbott Laboratories (Abbott Molecular)
- Affymetrix Inc
- Autogenomics
- Becton Dickinson and Company (BD)
- Beckmann Coulter, Inc (Danaher Corporation)
- bioMérieux
- Cancer Genetics, Inc
- Cepheid
- Dako (Agilent)
- Epigenomics
- Hologic Gen-Probe
- Illumina
- Ipsogen (Qiagen)
- Luminex
- MolecularMD
- Myriad Genetics Laboratories
- Novartis Diagnostics
- Ortho-Clinical Diagnostics (The Carlyle Group)
- Oxford Gene Technology (OGT)
- Qiagen N.V.
- Roche
- Siemens
- Sysmex Corporation
- Thermo Fisher Scientific
- Ventana (Roche)
Note: Product cover images may vary from those shown
5 of 4

Secondary Research

Typically, the secondary research process involves the use of secondary sources of information which includes internet research, the use of relevant databases, company annual reports and SEC documents and investor presentations. This process allows the collation of information on key players within the market of interest, an understanding of their products and service offerings and preliminary assessment of  the size of the market and key drivers and restraints impacting market growth. This process serves to inform appropriate market segmentation, market sizing and forecasting (bottom up and top down methodologies) and understanding of the competitive landscape.

Primary Research

Primary research involves in-depth telephone or face-to-face interviews with persons within the industries of interest. Interviews are conducted to obtain qualitative and quantitative information which is analysed to verify market sizing and forecasting and to provide insight into vital strategies deemed critical to market development. Analysts are experienced in interviewing industry experts at C-suite level and within sales and marketing and R&D functions within the biotechnology, pharmaceutical and medical device industries. For certain custom research projects, key opinion leaders across a range of therapeutic disciplines have been interviewed both through in-depth telephone interviews and on a face-to-face basis.

 

Loading
LOADING...

Adroll
adroll